TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Xenon ( (XENE) ) is now available.
On November 24, 2025, Xenon Pharmaceuticals Inc. amended its 2025 Inducement Equity Incentive Plan to increase the number of shares reserved for issuance from 775,000 to 900,000. This adjustment is intended to facilitate the granting of various stock-related incentives to new or returning employees without requiring shareholder approval, in line with Nasdaq Listing Rule 5635(c)(4).
The most recent analyst rating on (XENE) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on Xenon stock, see the XENE Stock Forecast page.
Spark’s Take on XENE Stock
According to Spark, TipRanks’ AI Analyst, XENE is a Neutral.
Xenon’s primary strengths lie in its strong financial position and positive clinical development progress, as highlighted in the earnings call. However, the absence of revenue and profitability, along with technical and valuation concerns, weigh heavily on the overall stock score.
To see Spark’s full report on XENE stock, click here.
More about Xenon
Average Trading Volume: 776,152
Technical Sentiment Signal: Buy
Current Market Cap: $3.46B
See more insights into XENE stock on TipRanks’ Stock Analysis page.